RESUMEN
BACKGROUND: Osteogenesis imperfecta (OI) is a genetic defect in collagen type I, phenotypically characterized by bony fragility and a propensity to high rates of childhood fracture. Fragility fractures in patients with OI have been reported with routine hospital care. In addition, there is a nonzero rate of iatrogenic fracture during orthopaedic surgery directly related to the technical steps of the procedure itself. The rate of this latter has never been explicitly investigated. METHODS: A review of all patients at a single OI referral center was conducted, including all patients with a diagnosis of OI seen between 2013 and 2023, inclusive. All patients who underwent orthopaedic surgery of any kind were reviewed, and clinical and radiographic details of all procedures were extracted. Among the details examined were the OI subtype, surgery details, any implants used, intraoperative and hospital stay complications, modified Clavien-Dindo classification of complications, and ultimate outcome. RESULTS: Eleven of 60 patients experienced an unplanned, iatrogenic intraoperative fracture during orthopaedic surgery (11/60 = 18.3%). This comprised 15 fractures among 356 total orthopaedic surgical episodes (15/356 = 4.2%). All but one fracture occurred on the operative long bone segment, all were a direct result of surgical steps, and 11 of 15 fractures occurred in the femur. Most fractures were secondary to the removal, insertion, or exchange of intramedullary implants in the lower extremity (11 of 15 fractures), most often the femur. Thirteen of 15 injuries were classified as modified Clavien-Dindo II or III, requiring modification of postop rehabilitation, additional treatments, or surgical intervention (87%). Overall, iatrogenic fracture was the most common intraoperative complication experienced in the cohort. CONCLUSIONS: Iatrogenic fracture during orthopaedic surgery for patients with OI is not uncommon. A sizeable minority of patients with OI undergoing orthopaedic surgery will experience unplanned fractures, most commonly in the femur, and care is altered in most instances. The risk of intraoperative fracture can be discussed with families of children with OI as part of informed consent and shared decision-making. LEVEL OF EVIDENCE: Level IV-retrospective cohort series.
RESUMEN
Background: Fatigue is one of the most disabling non-motor symptoms in PD. Researchers have previously used cut-offs validated in non-PD conditions when using the Fatigue Severity Scale (FSS) or the Multidimensional Fatigue Inventory (MFI) scores to evaluate fatigue in PD. Objective: We used a set of criteria for diagnosing clinically significant fatigue in PD to identify the proper cut-offs of the FSS and MFI. Methods: One hundred thirty-one PD patients (59F; age 67.3 ± 7.6 y; H&Y 1.6 ± 0.7) were assessed for clinically significant fatigue, followed by the FSS, MFI, Center for Epidemiologic Studies Depression Scale (CES-D), and Montreal Cognitive Assessment (MOCA). Mean scores were compared between 17 patients who met diagnostic criteria (significant fatigue group, SFG) and 114 who did not (non-significant fatigue group, NSFG). Results: The SFG had significantly higher scores in the 9-item FSS (p <.0001), total MFI score (p <.0001), and every MFI dimension except reduced motivation (p =.1) than the NSFG. Using area under the curve (AUC) of receiver operating characteristic (ROC) analyses, we recommend the following cut-offs: 9-item FSS 37; total MFI 60; general fatigue 11; reduced activity 10; physical fatigue 9; mental fatigue 9; and reduced motivation 9. Conclusions: The recommended cut-offs for clinically significant fatigue in the FSS, MFI, and MFI dimensions will be valuable for diagnosing clinically significant fatigue and for future studies in investigating pathophysiology and potential treatments of fatigue in PD.